« Back
Home /
Disufenton sodium

Disufenton sodium

Item no.	S6002-200
Manufacturer	Selleckchem
CASRN	168021-79-2
Amount	200 mg
Quantity options	10 mg 1 g 10 g 10 mM/1 ml 200 mg 50 mg 5 g
Category	Oncology Food Safety Proteins Neuroscience Neural Lineage Markers Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Smiles	CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NXY-059,Cerovive
Similar products	NXY-059
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	381, 33
Administration	Administered into the right jugular vein.
Animal Models	Monofilament fishing line is used to produce occlusion and neurologic deficit in male Wistar rats
Clinical Trials	NXY-059 is now under the Phase 2 clinical trial in patients with prelapsed or refractory multiple myeloma.
Dosages	0.3, 3.0 or 30 mg/kg
Formulation	NXY-059 is dissolved in physiological saline.
In vitro	NXY-059 is more soluble than the spin trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2]
In vivo	NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4]
Solubility (25C)	DMSO 76 mg/mL, Water 76 mg/mL, Ethanol 1 mg/mL
Information	Disufenton Sodium (NXY-059, Cerovive) is a novel nitrone, shows efficacious neuroprotective effects. Phase 3.
Chemical Name	1, 3-Benzenedisulfonic acid, 4-[[(1, 1-dimethylethyl)imino]methyl]-, N-oxide, disodium salt

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S6002-200-datasheet.pdf

S6002-200-safety-datasheet.pdf